ERBB2 and breast carcinoma: These additional datasets include the phosphoproteomics of patient-derived xenografts (PDX) of breast cancer tumors8, predominantly from HER2-negative patients, and the phosphoproteomics of HER2-positive breast cancer patients with data both before and 48–72 h after starting a combined chemotherapy and HER2-targeted therapy4.